Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 89 clinical trials
None
Reduced Intensity Partially HLA Mismatched BMT to Treat Hematologic Malignancies

If transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served. Towards this goal, the current study extends our platform of nonmyeloablative, partially HLA-mismatched bone marrow transplant (BMT) and Peripheral Blood Stem Cell Transplant (PBSCT) to the …

total body irradiation
lymphoma
cancer
leukemia
mantle cell lymphoma
  • 17 views
  • 01 Feb, 2021
  • 1 location
None
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma

Monocentric randomized phase I/II trial, including 24 patients diagnosed with relapsing glioblastoma (GBM) irrespective of MGMT and IDH gene status. Following diagnosis of relapsing glioblastoma by either brain CT scan or MRI, patients will be randomized in 2 arms: Arm 1: IMA950 mixed with Poly-ICLC administered subcutaneously Arm 2: Pembrolizumab …

measurable disease
dexamethasone
poly iclc
  • 46 views
  • 28 Jan, 2021
  • 1 location
None
Allogeneic Hematopoietic Stem Cell Transplant for People With Primary Immunodeficiency Diseases

Background During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective To see if stem cell transplant can …

therapeutic agents
total body irradiation
hypogammaglobulinemia
cancer
conjugated bilirubin
  • 0 views
  • 12 Sep, 2021
  • 1 location
None
Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

This study aims to enroll 58 pre-adolescent (<13 years) pediatric participants with sickle cell disease (SCD) who have a pre-adolescent sibling bone marrow donor. All participants will go through a pre-transplant evaluation to find out if there are health problems that will keep them from being able to receive the …

transplant conditioning
transcranial doppler ultrasonography
blood transfusion
cell transplantation
arteriopathy
  • 23 views
  • 24 Sep, 2021
  • 10 locations
None
Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation

For several decades, allogeneic hematopoietic stem cell trans-plantation (allo-HSCT) has remained an important strategy in the management of patients with high-risk hematological malignancies. The acceptance of umbilical cord blood (UCBT) and haploidentical grafts (Haplo) as viable alternative donors for allo-HSCT has increased the options for patients with no matched donors …

chronic lymphocytic leukemia
remission
lymphoma
cancer
leukemia
  • 0 views
  • 06 Mar, 2021
  • 1 location
None
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.

nephropathy
malignant disease
osteonecrosis
conjugated bilirubin
blood transfusion
  • 18 views
  • 19 Oct, 2021
  • 1 location
None
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will also be trying to …

platelet count
solid tumour
renal function
metastasis
kidney function tests
  • 12 views
  • 16 Jun, 2021
  • 4 locations
None
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-01 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies.

cancer
EGFR
solid tumour
metastasis
primary cancer
  • 0 views
  • 21 Oct, 2021
  • 10 locations
None
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose esophageal or esophagogastric junction (EGJ) cancer expresses the MAGE-A4 protein.

measurable disease
esophagus cancer
  • 0 views
  • 30 Sep, 2021
  • 9 locations
None
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies

This clinical pilot trial is intended to evaluate the feasibility, efficacy and safety of hematopoietic stem cell transplantation (HSCT) from Human Leukocyte Antigen (HLA)-mismatched related donors for children and young adults with hematologic malignancies who lack a suitably matched related or unrelated donor. The methodology will be one that has …

lymphoma
lymphoid leukemia
cancer
leukemia
cyclophosphamide
  • 54 views
  • 16 Mar, 2021
  • 1 location